82,737 results match your criteria non-small-cell lung


A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.

Cancer Treat Res Commun 2021 Jun 9;28:100416. Epub 2021 Jun 9.

University of Washington, Department of Medicine, Division of Medical Oncology United States.

Background: Patients with metastatic non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation have effective targeted therapy options initially but most patients eventually progress and receive cytotoxic chemotherapy. In this single-institution phase II study, we evaluated the role of nab-paclitaxel monotherapy in this patient population.

Patients And Methods: Patients with metastatic NSCLC with an activating EGFR mutation whose disease progressed after frontline tyrosine kinase inhibitor therapy and who were chemotherapy naïve received nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in a 28-day cycle. Read More

View Article and Full-Text PDF

Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.

Am J Kidney Dis 2021 Jun 9. Epub 2021 Jun 9.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. Electronic address:

We present a case of pseudo acute kidney injury (AKI) following capmatinib therapy in an 84-year-old male with combined non-small cell (adenocarcinoma) and small cell lung cancer with MET Exon 14 skipping mutation. His past medical history was significant for chronic kidney disease (CKD) stage 3 with a baseline serum creatinine (SCr) of 1.6 mg/dl rising to 2. Read More

View Article and Full-Text PDF

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

Lancet Oncol 2021 Jun 9. Epub 2021 Jun 9.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

Methods: ARROW is a multi-cohort, open-label, phase 1/2 study done at 71 sites (community and academic cancer centres) in 13 countries (Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, the UK, and the USA). Read More

View Article and Full-Text PDF

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.

Clin Pharmacol Drug Dev 2021 Jun 12. Epub 2021 Jun 12.

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Mobocertinib (TAK-788) is a tyrosine kinase inhibitor under investigation for treatment of non-small cell lung cancer with activating EGFR exon 20 insertions. This study examined the safety; tolerability; pharmacokinetics (PK), including food effects; and bioavailability of mobocertinib in healthy volunteers. In part 1, fasted volunteers were randomized to placebo or mobocertinib in single-ascending-dose cohorts (20-160 mg). Read More

View Article and Full-Text PDF

How should we manage non-small-cell lung cancer "not-otherwise-specified"?

Med Oncol 2021 Jun 12;38(7):82. Epub 2021 Jun 12.

Department of Respiratory Medicine, Takatsuki General Hospital, 1-3-13 Kosobe-cho, Takatsuki, Osaka, 569-1192, Japan.

View Article and Full-Text PDF

The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.

J Cell Mol Med 2021 Jun 11. Epub 2021 Jun 11.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Despite the previous evidence showing that SHC adaptor protein 1 (SHC1) could encode three distinct isoforms (p46SHC, p52SHC and p66SHC) that function in different activities such as regulating life span and Ras activation, the precise underlying role of SHC1 in lung cancer also remains obscure. In this study, we firstly found that SHC1 expression was up-regulated both in lung adenocarcinoma (LUAD) and in lung squamous cell carcinoma (LUSC) tissues. Furthermore, compared to patients with lower SHC1 expression, LUAD patients with higher expression of SHC1 had poorer overall survival (OS). Read More

View Article and Full-Text PDF

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Oncol Ther 2021 Jun 11. Epub 2021 Jun 11.

Programa de Pós-Graduação Em Medicamentos E Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Introduction: Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2-5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment. Read More

View Article and Full-Text PDF

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.

Int J Clin Oncol 2021 Jun 11. Epub 2021 Jun 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Background: We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC).

Methods: The study included patients with EGFR activating mutation-positive advanced NSCLC who were positive for T790M in tumor tissue or plasma after previous treatment with an EGFR tyrosine kinase inhibitor, who received osimertinib at Kindai University Hospital between August 2014 and September 2017, and for whom plasma collected after progression on osimertinib was available. Clinical data were extracted from medical records. Read More

View Article and Full-Text PDF

Mass spectrometry imaging of L-[ring-C]-labeled phenylalanine and tyrosine kinetics in non-small cell lung carcinoma.

Cancer Metab 2021 Jun 11;9(1):26. Epub 2021 Jun 11.

Maastricht MultiModal Molecular Imaging institute (M4I), Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.

Background: Metabolic reprogramming is a common phenomenon in tumorigenesis and tumor progression. Amino acids are important mediators in cancer metabolism, and their kinetics in tumor tissue are far from being understood completely. Mass spectrometry imaging is capable to spatiotemporally trace important endogenous metabolites in biological tissue specimens. Read More

View Article and Full-Text PDF

Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.

J Thorac Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Japan.

Introduction: About 10% of locally-advanced non-small cell lung cancer (LA-NSCLC) patients harbor epidermal growth factor receptor (EGFR) mutation and recent reports suggested the declined benefit with immune-checkpoint inhibitor in this population. The attempt that introduces EGFR-tyrosine kinase inhibitor (TKI) into the treatment of LA-NSCLC with EGFR mutation has been warranted.

Methods: Chemotherapy-naïve, unresectable LA-NSCLC patients with sensitive EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were enrolled. Read More

View Article and Full-Text PDF

The Novel FAT4 Activator Jujuboside A Suppresses NSCLC Tumorigenesis by Activating HIPPO Signaling and Inhibiting YAP Nuclear Translocation.

Pharmacol Res 2021 Jun 8:105723. Epub 2021 Jun 8.

Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, PR China; State Key Laboratory of Quality Research in Chinese Medicine/ Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau (SAR), China. Electronic address:

FAT atypical cadherin 4 (FAT4) has been identified as a tumor suppressor in lung cancers. However, no agent for lung cancer treatment targeting FAT4 has been used in the clinic. Jujuboside A (JUA) is a major active compound in Semen Ziziphi Spinosae. Read More

View Article and Full-Text PDF

Correlation between the number of viable tumor cells and immune cells in the tumor microenvironment in non-small cell lung cancer after induction therapy.

Pathol Int 2021 Jun 11. Epub 2021 Jun 11.

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

This study aims to determine the correlation between the percent viable tumor cells (%VTC) and the tumor microenvironment in resected non-small cell lung cancer after induction therapy. We enrolled 72 patients with non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT) or chemotherapy (CT) prior to surgery. The ratio of the area of viable tumor cells to the total tumor area was calculated to obtain the %VTC. Read More

View Article and Full-Text PDF

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.

Jpn J Clin Oncol 2021 Jun 12. Epub 2021 Jun 12.

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Background: In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients.

Methods: Chemo-naïve patients with EGFR-mutant advanced non-small-cell lung cancer were enrolled. Read More

View Article and Full-Text PDF

B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.

Immunology 2021 Jun 11. Epub 2021 Jun 11.

Department of Immunology, Nantong University, School of Medicine, Nantong, Jiangsu, 226001, China.

Loss of the B2M gene is associated with tumor immune escape and resistance to immunotherapy. However, genetic alterations of the B2M gene are rare. We performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non-small-cell lung cancer (NSCLC) patients and found that epigenetic downregulation of B2M is common. Read More

View Article and Full-Text PDF

LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p.

Mol Biotechnol 2021 Jun 11. Epub 2021 Jun 11.

Department of Thoracic Surgery, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun, 130041, Jilin, China.

This study revealed the prognostic significance of long non-coding RNA (lncRNA) CCDC144NL-AS1 in NSCLC patients and discussed the effect and mechanism of proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells. 128 pairs of NSCLC tissues and paracancerous tissues were collected, and qRT-PCR was used to detect the differential expression of lncRNA CCDC144NL-AS1 in all tissues and cells lines. Kaplan-Meier analysis and Cox proportional hazards model analysis were used to estimate the prognostic value of lncRNA CCDC144NL-AS1. Read More

View Article and Full-Text PDF

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

J Natl Cancer Inst 2021 Jun 11. Epub 2021 Jun 11.

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, 677 Huntington Ave, Boston, MA, USA.

Background: Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a subset of patients, consistent and easily obtainable predictors of efficacy remain elusive.

Methods: This study was conducted on 644 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy between April 2013 and September 2020 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Patient smoking history, clinicopathological characteristics, tumor mutation burden (TMB) by clinical targeted next generation sequencing, and PD-L1 tumor proportion score (TPS) by immunohistochemistry were prospectively collected. Read More

View Article and Full-Text PDF

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.

Medicine (Baltimore) 2021 Jun;100(23):e25709

People's Hospital of Changxing, Huzhou, Zhejiang, China.

Purpose: In this meta-analysis and systemic review, we focused on the effectiveness and safety of anlotinib in patients with advanced non-small cell lung cancer(NSCLC).

Methods: The databases of PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and CBM were searched by 2 investigators up to April 2020. Titles and abstracts of all records were screened and eligible publications were retrieved in full. Read More

View Article and Full-Text PDF

Efficacy of immunotherapy in -mutant non-small-cell lung cancer with comutations.

Immunotherapy 2021 Jun 11. Epub 2021 Jun 11.

Department of Medical Oncology, Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW 2050, Australia.

-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No  specific therapy has been approved by the FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. Read More

View Article and Full-Text PDF

Mediastinal lymph node dissection: punishment or discipline?

Eur J Cardiothorac Surg 2021 Jun 11. Epub 2021 Jun 11.

Department of Thoracic Surgery, Ramón y Cajal University Hospital, Madrid, Spain.

View Article and Full-Text PDF

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.

Front Oncol 2021 25;11:635007. Epub 2021 May 25.

Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), have dramatically improved the survival and quality of life of a subset of non-small cell lung cancer (NSCLC) patients. Multiple predictive biomarkers have been proposed to select the patients who may benefit from the immune checkpoint inhibitors. Read More

View Article and Full-Text PDF

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells.

Oncol Lett 2021 Jul 29;22(1):569. Epub 2021 May 29.

Obstetrics and Gynecology Department, Maternal and Child Health Hospital of Zibo City, Zibo, Shandong 255022, P.R. China.

Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non-small cell lung cancer, head and neck cancer, few studies report its effectiveness in drug-resistant human OC cells. In the present study, would healing, microplate spectrophotometer analysis, flow cytometry analysis, western blotting and Gene Expression Omnibus (GEO) analysis were used to detect the synergistic effect of dacomitinib and cisplatin in human OC SKOV-3 or OV-4 cells. Read More

View Article and Full-Text PDF

LncRNA PVT1 Facilitates Proliferation, Migration and Invasion of NSCLC Cells via miR-551b/FGFR1 Axis.

Onco Targets Ther 2021 2;14:3555-3565. Epub 2021 Jun 2.

Department of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.

Background: Long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) plays a crucial role in non-small cell lung cancer (NSCLC). Nonetheless, regulatory effects of PVT1 on functions of NSCLC cells remain blurry.

Methods: Relative expression levels of PVT1, miR-551b and FGFR1 mRNA in tumor tissues and cells were examined employing quantitative real-time polymerase chain reaction (qRT-PCR); CCK-8 and BrdU assays were utilized for measuring cell viability and proliferation of H1299 and A549 cells; cell migration and invasion were detected deploying Transwell assay; dual-luciferase assay was used for the validation of binding sequence between PVT1 and miR-551b. Read More

View Article and Full-Text PDF

Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer.

BMC Complement Med Ther 2021 Jun 10;21(1):169. Epub 2021 Jun 10.

Academy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.

Background: Non-small-cell lung cancer (NSCLC) accounts more than 80% of the lung cancer cases. Polysaccharides in rice bran and its fermentation products have been proven to suppress many cancers. However, the report on inhibiting NSCLC is few. Read More

View Article and Full-Text PDF

GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.

BMC Pulm Med 2021 Jun 10;21(1):199. Epub 2021 Jun 10.

Molecular Oncology Department of Cancer Research Institution, The First Hospital of China Medical University, Nanjingbei Street, Heping District, Shenyang, 110001, Liaoning Province, China.

Background: Glypican 3 (GPC3) is a heparin sulphate proteoglycan whose expression is associated with several malignancies. However, its expression in non-small-cell lung carcinoma (NSCLC) is limited and ambiguous. This study aimed to comprehensively evaluate the expression of GPC3 in NSCLC and develop a risk-score model for predicting the prognosis of NSCLC. Read More

View Article and Full-Text PDF

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

BMC Cancer 2021 Jun 10;21(1):689. Epub 2021 Jun 10.

Hospital Universitario Fundacion Jimenez Diaz - CIBERONC, Madrid, Spain.

Background: Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for an adequate treatment decision. The aim of this study is to determine the clinical and economic impact of current anaplastic lymphoma kinase testing scenario in Spain. Read More

View Article and Full-Text PDF

Monitoring HOTTIP levels on extracellular vesicles for predicting recurrence in surgical non-small cell lung cancer patients.

Transl Oncol 2021 Jun 7;14(8):101144. Epub 2021 Jun 7.

Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, Faculty of Medicine and Health Sciences, University of Barcelona, IDIBAPS, Casanova 143, 08036 Barcelona, Spain; Thoracic Oncology Unit, Hospital Clinic, Barcelona. Electronic address:

In resected non-small cell lung cancer (NSCLC), postsurgical recurrence is the major factor affecting long-term survival. The identification of biomarkers in extracellular vesicles (EV) obtained from serial blood samples after surgery could enhance early detection of relapse and improve NSCLC outcome. Since EV cargo contains long non-coding RNAs (lncRNAs), we aimed to analyze whether the oncogenic lncRNA HOTTIP, which higher expression in tumor tissue was related to worse outcome in NSCLC, could be detected in EV from NSCLC patients and serve as recurrence biomarker. Read More

View Article and Full-Text PDF

Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.

Lung Cancer 2021 May 27;158:40-46. Epub 2021 May 27.

Division of Nuclear Medicine, European Institute of Oncology, IRCCS, Milan, Italy.

Objectives: Pleomorphic lung carcinoma (PLC) is a rare histotype of non-small cell lung cancer (NSCLC) characterized by aggressive clinical course, poor response to therapy and poor prognosis. Therefore, aim of our study is to analyze with 18F-FDG PET/CT a subset of patients affected by PLC to evaluate their metabolic characteristics in terms of SUVmax, MTV and TLG, in order to correlate them with overall survival (OS) and disease-free survival (DFS).

Material And Methods: We retrospectively analyzed 49 consecutive patients with histologically defined PLC occurred to our Institution between 2003 and 2014. Read More

View Article and Full-Text PDF

The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance.

Expert Rev Anticancer Ther 2021 Jun 10. Epub 2021 Jun 10.

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Introduction: Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to the long-term survival of -rearranged non-small cell lung cancer (NSCLC) patients. Based on clinical trial data, treatment with second- or third-generation ALK inhibitors can be initiated after crizotinib therapy without analyzing resistance mechanisms, and some randomized trials have recently shown the superiority of second- or third-generation ALK inhibitors over crizotinib as the initial treatment; however, the optimal treatment for patients who relapse while on second- or third-generation ALK inhibitors is not well-defined.

Areas Covered: This review provides an overview of the mechanisms of resistance to second- or third-generation ALK inhibitors that have been identified in both clinical and pre-clinical settings, and introduces strategies for overcoming resistance and discusses ongoing clinical trials. Read More

View Article and Full-Text PDF